Business Description
Agios Pharmaceuticals is a US-based drug development company focused on treating blood disorders by targeting how cells produce and use energy. Its main product, PYRUKYND, is approved for adults with pyruvate kinase deficiency and is being tested for sickle cell disease and use in children, while a related treatment called AQVESME addresses a range of thalassemia conditions. The company also has several other therapies in development targeting rare blood and genetic disorders. Founded in 2007 and based in Cambridge, Massachusetts, Agios continues to build a pipeline aimed at diseases with limited existing treatment options.
